Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03933449 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | completed | Phase 3 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Mar 29, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER |
| 1 |
| Mar 23, 2023 |
| clinicaltrials |
| NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer(Ultimate) | completed | Phase 3 | 166 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT01850303 | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer(MODEL) | completed | Phase 3 | 632 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | completed | Phase 3 | 628 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 13, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients(eNERGY) | completed | Phase 3 | 217 | Rennes University HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | completed | Phase 3 | 290 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03856411 | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | completed | Phase 3 | 465 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03196986 | mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 517 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02420821 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)(IMmotion151) | completed | Phase 3 | 915 | Hoffmann-La RocheINDUSTRY | 21 | Jan 30, 2023 | clinicaltrials |
| NCT02438436 | Simo Decoction and Gum Chewing for Bowel Activity(SD/GC-HCC) | completed | Phase 3 | 180 | Guangxi Medical UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein(REACH-2) | completed | Phase 3 | 399 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 20, 2023 | clinicaltrials |
| NCT03682224 | Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients(BEMP) | completed | Phase 3 | 57 | Southern Illinois UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02813785 | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy(IMpower210) | completed | Phase 3 | 565 | Hoffmann-La RocheINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT00473343 | Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma | completed | Phase 3 | 102 | Galderma R&DINDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT01414608 | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | completed | Phase 3 | 926 | GOG FoundationNETWORK | 5 | Nov 7, 2022 | clinicaltrials |
| NCT02144077 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy | completed | Phase 3 | 281 | Biofrontera Bioscience GmbHINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02460419 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | completed | Phase 3 | 104 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02066636 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen(CheckMate153) | completed | Phase 3 | 1,428 | Bristol-Myers SquibbINDUSTRY | 2 | Oct 27, 2022 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT01968941 | Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients(LUSTRE) | completed | Phase 3 | 324 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT03922997 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 101 | Hoffmann-La RocheINDUSTRY | 1 | Sep 9, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT01535053 | Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia | completed | Phase 3 | 57 | GOG FoundationNETWORK | 5 | Aug 12, 2022 | clinicaltrials |
| NCT01668784 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | completed | Phase 3 | 821 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 9, 2022 | clinicaltrials |
| NCT04342377 | The Canada Lymph Node Score Project: A Crossover Trial(CLNS) | completed | Phase 3 | 80 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | completed | Phase 3 | 903 | Cellectar Biosciences, Inc.INDUSTRY | 12 | Jul 25, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | completed | Phase 3 | 540 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 6 | Jul 13, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT00913705 | Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer(NATCH) | completed | Phase 3 | 624 | Spanish Lung Cancer GroupOTHER | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | completed | Phase 3 | 305 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT02383966 | Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer(CHANGE2) | completed | Phase 3 | 243 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT01517802 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | completed | Phase 3 | 32 | Janssen Research & Development, LLCINDUSTRY | 7 | May 10, 2022 | clinicaltrials |
| NCT01137123 | Improve the Treatment of Thoracic Esophageal Cancer | completed | Phase 3 | 301 | Sun Yat-sen UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04633564 | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC | completed | Phase 3 | 671 | Mylan Pharmaceuticals IncINDUSTRY | 17 | Mar 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 29, 2023source: clinicaltrials